Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.02 USD
Change Today -1.14 / -5.14%
Volume 268.0K
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

intra-cellular therapies inc (ITCI) Snapshot

Open
$22.15
Previous Close
$22.16
Day High
$22.52
Day Low
$20.64
52 Week High
02/18/15 - $30.72
52 Week Low
09/23/14 - $12.67
Market Cap
735.0M
Average Volume 10 Days
214.7K
EPS TTM
$-1.61
Shares Outstanding
35.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTRA-CELLULAR THERAPIES INC (ITCI)

Related News

No related news articles were found.

intra-cellular therapies inc (ITCI) Related Businessweek News

No Related Businessweek News Found

intra-cellular therapies inc (ITCI) Details

Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression, and other neuropsychiatric and neurological disorders. The company also develops ITI-002 program that is in phase 1 development for the treatment of central nervous system, cardiovascular, and other disorders. Intra-Cellular Therapies, Inc. has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize its proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.

intra-cellular therapies inc (ITCI) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $954.0K
Co-Founder and Vice President of Business Dev...
Total Annual Compensation: $283.7K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $386.3K
Senior Vice President, General Counsel and S...
Total Annual Compensation: $207.5K
Vice President of Corporate Communications & ...
Total Annual Compensation: $294.4K
Compensation as of Fiscal Year 2014.

intra-cellular therapies inc (ITCI) Key Developments

Intra-Cellular Therapies, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Intra-Cellular Therapies, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $22,286,824, or $0.72 per basic and diluted share, compared with a net loss of $4,543,284 or $0.17 per basic and diluted share a year ago. Revenues were $3,315 against $167,787 a year ago. Loss from operations was $22,400,740 against $4,574,463 a year ago. Research and development (R&D) expenses were $18.6 million, compared to $2.8 million for the first quarter of 2014. The increase is due primarily to costs associated with program ITI-007 Phase 3 clinical trial which was initiated in late 2014.

Intra-Cellular Therapies, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Intra-Cellular Therapies, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research

Intra-Cellular Therapies, Inc. presented data regarding the ITI-007 development program and described the rationale supporting the strategy for the advancement of ITI-007 in multiple clinical indications at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs. In a poster the company described the rationale for dose selection in the ongoing Phase 3 clinical trial in schizophrenia. Preclinical data predicted antipsychotic efficacy at human equivalent doses as low as 20 – 40 mg of ITI-007. Positron emission tomography (PET) data in healthy volunteers demonstrated striatal D2 receptor occupancy of ~20% and ~40% at doses of 20 mg and 40 mg, respectively. Striatal D2 receptor occupancy at 60 mg was projected to be approximately 50%. In a Phase 2 clinical trial in patients with schizophrenia, ITI-007 at a dose of 60 mg demonstrated a statistically significant and clinically meaningful improvement in psychosis with a favorable metabolic, cardiovascular and motor adverse event profile. Based on the preclinical and clinical results described above the company selected doses of 60 mg and 40 mg of ITI-007 for the ongoing Phase 3 clinical trial in schizophrenia. This study, ITI-007-301, is a randomized, double-blind, placebo-controlled, inpatient clinical trial in patients with an acutely exacerbated episode of schizophrenia. In this trial, over 400 patients are expected to be randomized to receive one of three treatments: 60 mg ITI-007, 40 mg ITI-007 or placebo in a 1:1:1 ratio. The company anticipates topline results from this trial will be available in the second half of 2015. In an oral presentation the company summarized the clinical progress of ITI-007 to date and emphasized its rationale supporting the development of ITI-007 for other indications. ITI-007 has a unique pharmacological profile acting as a serotonergic, dopaminergic, and glutamatergic modulator. In addition, ITI-007 has a dose-dependent pharmacology. At low doses, ITI-007 acts mainly as a potent 5-HT2A receptor antagonist, with modest interaction with other drug targets. As the dose is increased, additional pharmacological interactions play a greater role, i.e., dopamine and glutamate receptor modulation and inhibition of SERT are gradually increased. The company emphasized the pharmacological, pharmacodynamic and safety profile of ITI-007, which supports its development in other indications beyond schizophrenia, including bipolar disorder and major depressive disorder as well as behavioral disturbances in patients with dementia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITCI:US $21.02 USD -1.14

ITCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITCI.
View Industry Companies
 

Industry Analysis

ITCI

Industry Average

Valuation ITCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,652.0x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,307.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTRA-CELLULAR THERAPIES INC, please visit www.intracellulartherapies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.